Avoro Capital Advisors SNDX Position
Exited8-Fund ConvergenceAvoro Capital Advisors exited their position in Syndax Pharmaceuticals Inc. (SNDX) in Q1 2025, after holding the stock for 9 quarters.
The position was first reported in Q1 2023 and has been tracked across 9 quarterly 13F filings.
SNDX is a convergence signal: 8 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Axatilimab in 167 days (Sep 30, 2026), making the timing of Avoro Capital's position particularly relevant.
Short interest stands at 26.1% of float with 15.1 days to cover, indicating significant bearish positioning against the stock.
About Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.
Full company profile →Short Interest
26.1%
15.1 days to cover
Avoro Capital Advisors SNDX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q1 2025 | Exited | 0 | -2,275,000 | $0 |
| Q4 2024 | Decreased | 2,275,000 | -1,613,437 | $30.1M |
| Q3 2024 | Held | 3,888,437 | — | $74.9M |
| Q2 2024 | Decreased | 3,888,437 | -333,785 | $79.8M |
| Q1 2024 | Held | 4,222,222 | — | $100.5M |
| Q4 2023 | Increased | 4,222,222 | +1,666,667 | $91.2M |
| Q3 2023 | Decreased | 2,555,555 | -94,445 | $37.1M |
| Q2 2023 | Held | 2,650,000 | — | $55.5M |
| Q1 2023 | New | 2,650,000 | +2,650,000 | $56.0M |
Frequently Asked Questions
Does Avoro Capital Advisors own SNDX?
No. Avoro Capital Advisors exited their position in Syndax Pharmaceuticals Inc. (SNDX) in Q1 2025. They previously held the stock for 9 quarters.
How many hedge funds own SNDX?
8 specialist biotech hedge funds currently hold SNDX, including OrbiMed Advisors, BVF Partners, Eventide Asset Management and 5 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Avoro Capital Advisors first buy SNDX?
Avoro Capital Advisors's position in SNDX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Avoro Capital Advisors's SNDX position increasing or decreasing?
Avoro Capital Advisors completely exited their SNDX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
SNDXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Avoro Capital AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →